Small Molecule API Market: APEJ Projected to be the Most Lucrative Regional Market During the Forecast Period: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027
- REP-GB-4591
- 2017-08-08
- Category: Healthcare, Pharmaceuticals and Medical devices
- 209 Pages
- Format:
Global scenario of the small molecule API market – moderate growth rate observed
The global small molecule API market is anticipated to grow at a moderate rate to register a CAGR of 4.9% during the period of forecast, 2017-2027. There are several aspects that govern the growth rate of the global small molecule API market. The key drivers fuelling the growth of the market are factors such as rise in small molecule API growth, the HPAPI witnessing higher boost in growth rate, and the pharmerging countries being explored as alternative sourcing destinations. Trends such as the sourcing of the APIs done from Indian pharmaceutical manufacturers based in the U.S and higher investment in infrastructural facilities in order to raise the in-house production also contribute to the growth of the global small molecule API market. Moreover, owing to these drivers and trends, there are certain opportunities that lurk within the global small molecule API market. To name a few – the growth in healthcare spending in developing nations such as Asia Pacific and other regions and expansion with respect to product offerings as well as reduction in the costs involved.
Asia Pacific excluding Japan to grow at full speed and gain high market share
Asia Pacific excluding Japan (APEJ) reflects higher speed by registering a growth rate of 5.8% during the forecast period 2017 to 2025. The Asian countries hold significant revenue share in the entire market. Most of the anti-inflammatory drugs as well as antibiotic drugs are produced in the Asian counties, with China and India topping the list. Almost 80% of the total antibiotic APIs are produced in China and India and most of these APIs are outsourced to developed regions such as Europe and North America. The main reasons for this to be possible is the abundant availability of raw material needed to produce APIs, and the availability of low cost labour in India and China. Additionally, these regions enjoy a favourable regulatory assistance along with low taxation policies in order to establish API manufacturing businesses. Also, a large patient population consumes non-controlled drugs, which makes Asia Pacific excluding Japan experience a higher in-house API consumption. The APEJ region also reflects a high market attractiveness and higher market share of almost 34% estimated to be held in 2017. This percentage is expected to rise even higher by the end of 2027, following the major trends that push the growth of the global small molecule API market in the APEJ region.
The pharma companies in India had filed DMFs making India the leading country in DMF filing. This infers that in the near future, majority of the API manufacturing contracts from U.S. based companies would be awarded to India based companies. Moreover, the rapid rise in the Indian generics market will also fuel the API market growth in this region.
Trend analysis in the APEJ market – raising the bar of growth in the region
The Asia Pacific excluding Japan region is all set to experience a tremendous growth rate during the forecast period. The APEJ small molecule API market is expected to show a high figure of more than US$ 52 Bn by the end of 2027 and dominate the global market. The main reason for this growth is the high outsourcing in this region. Developing nations of China and India lead by SMEs. The production in these countries is rising owing to limited regulatory coverage. Also, the in-house consumption in India is higher, which has resulted in increased focus on the manufacturing of APIs in India.
The distribution network is also extensive in the overseas markets especially in regions such as Europe, United States and South Africa. Another factor supporting the statement that APEJ is experiencing higher growth is – Indian companies manufacturing APIs are taking advantage of the export opportunities especially in the Latin America region. All these trends are aiding the facts that are favourable for the growth of the small molecule API market in the APEJ region. The region that is the most growing and anticipated to grow even further is China, which shows a higher growth rate to register a CAGR of 6.9% followed by India.
The in-depth and thorough report titled “Small Molecule API Market: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027” gives the reader a feel and flavour of the market understanding with a wide overview of the market thereby supporting decision making and slating different strategies as and when required.
An exhaustive market research report on the small molecule API market offers weighted analysis of the entire market. Focussing on the major segments and covering all factors that have an influence over the market helps predict the growth rate of the market in the particular regions. Below sketched is the market taxonomy that covers all the segments of the global small molecule API market.
|
Molecule |
Production |
Application |
Therapeutic Area |
Region |
|---|---|---|---|---|
|
|
|
|
|
This research study on the small molecule API market delivers value to the reader by making them aware about the past and present scenario of the market. The study also uncovers predictions of the future thereby giving an inkling about the small molecule API market scenario 10 years down the line. It emphasises on the various intelligence acumen such as pricing, product portfolio of various key players present in the market, distribution channel analysis, key developments, trends in present and future, a complete SWOT analysis along with PESTLE analysis and also analysis of the important regions assessed. The study covers revenue generated by API manufacturing including in-house and outsourced manufacturing. The report analyses the demand from in-house production as well as outsourced API production. These insights help plan future decisions and strategic moves that could be easily executed owing to the actionable nature of the understandings present in the report.
An effective research process to ensure maximum proficiency
At Future Market Insights, the analysts follow a rock-solid research process to allow minimum deviations in the research and reach maximum accuracy. In order to get a 3600 view of the market, a strong secondary research is carried out. Assistance of secondary paid sources is just enough to get going in the correct direction. The secondary research gives a direction to the market definition based on which several primary interviews are carried out. Key decision makers from several companies within the market are interviewed as well as opinions of market observers are gathered. The data collected from the secondary sources and the corresponding data gathered by primaries is collated and each data point is verified while conversing with the market experts. The best part of this unique methodology is that the data so gathered undergoes evaluation and validation again and again which makes the intelligence extremely accurate giving a realistic shape to the market scenario. A holistic view of the market thus ensures timely and effective strategies to be implemented owing to the data crunching done with reduced or eliminated deviations from the actual face value of the market.
Competition analysis
The research study provides a separate chapter on the competitive landscape, which covers all the major players in the market, along with their details. Facets such as product portfolio analyses, mergers and acquisitions, developments and innovations, key trends followed, market shares and revenues, geographical spread and expansion plans, marketing strategies and pricing intelligence, etc. of the key players are focussed upon. This helps the reader freeze their own milestones and the various strategic moves required to achieve those milestones. The key players include all the tier companies that have a firm hold over the market and can be said to be the face of the market. The intelligence provided on these players enables the reader to understand the “not-to-do” aspects and how to set foot in the right direction.
The key value additions that the report offers:
- The entire report gives credible information with an unbiased interpretation, considering all the possible angles and giving it a holistic view
- The report gives details about each segment present in the market with respect to all important geographies
- The research study enables unparalleled accuracy owing to the use of a robust research methodology
- The research on the past and the present scenario in the global market can give actionable insights on the future; a separate dedicated section on the forecasts helps the reader analyse present moves and predict future actions
- In-depth analysis covers everything giving justice to each segment involved
- The trends, developments, innovations, restraints and challenges faced by every facet is also covered giving a total briefing about the market and uncovering the possible loop holes
Small Molecule Api Market Reports - Table of Contents
1. Executive Summary
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Small Molecule Active Pharmaceutical Ingredient Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Scenario
3.4. Pipeline Assessment
4. North America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Pestle Analysis
4.3. Regional Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends
4.4. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
4.4.1. U.S.
4.4.2. Canada
4.5. Market Size (US$ Mn) Forecast By Country, 2017–2027
4.5.1. U.S.
4.5.2. Canada
4.6. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
4.6.1. Standard API
4.6.2. High Potency API
4.7. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
4.7.1. Standard API
4.7.2. High Potency API
4.8. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
4.8.1. In-House
4.8.2. Outsourced
4.9. Market Size (US$ Mn) Forecast By Production, 2017–2027
4.9.1. In-House
4.9.2. Outsourced
4.10. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
4.10.1. Clinical
4.10.2. Commercial
4.11. Market Size (US$ Mn) Analysis By Application, 2017–2027
4.11.1. Clinical
4.11.2. Commercial
4.12. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
4.12.1. Cardiovascular
4.12.2. Respiratory
4.12.3. Infectious
4.12.4. Metabolic
4.12.5. Oncology
4.12.6. Immunology
4.12.7. Neurology
4.12.8. Urology
4.12.9. Dermatology
4.12.10. Ophthalmology
4.12.11. General Health
4.12.12. Others
4.13. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
4.13.1. Cardiovascular
4.13.2. Respiratory
4.13.3. Infectious
4.13.4. Metabolic
4.13.5. Oncology
4.13.6. Immunology
4.13.7. Neurology
4.13.8. Urology
4.13.9. Dermatology
4.13.10. Ophthalmology
4.13.11. General Health
4.13.12. Others
4.14. Drivers and Restraints: Impact Analysis
4.15. Market Attractiveness Analysis
4.15.1. By Country
4.15.2. By Molecule Type
4.15.3. By Production
4.15.4. By Application
4.15.5. By Therapeutic Area
4.16. Key Representative Market Participants
4.17. Market Presence (Intensity Map)
5. Latin America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
5.5.1. Standard API
5.5.2. High Potency API
5.6. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
5.6.1. Standard API
5.6.2. High Potency API
5.7. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
5.7.1. In-House
5.7.2. Outsourced
5.8. Market Size (US$ Mn) Forecast By Production, 2017–2027
5.8.1. In-House
5.8.2. Outsourced
5.9. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
5.9.1. Clinical
5.9.2. Commercial
5.10. Market Size (US$ Mn) Analysis By Application, 2017–2027
5.10.1. Clinical
5.10.2. Commercial
5.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
5.11.1. Cardiovascular
5.11.2. Respiratory
5.11.3. Infectious
5.11.4. Metabolic
5.11.5. Oncology
5.11.6. Immunology
5.11.7. Neurology
5.11.8. Urology
5.11.9. Dermatology
5.11.10. Ophthalmology
5.11.11. General Health
5.11.12. Others
5.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
5.12.1. Cardiovascular
5.12.2. Respiratory
5.12.3. Infectious
5.12.4. Metabolic
5.12.5. Oncology
5.12.6. Immunology
5.12.7. Neurology
5.12.8. Urology
5.12.9. Dermatology
5.12.10. Ophthalmology
5.12.11. General Health
5.12.12. Others
5.13. Drivers and Restraints: Impact Analysis
5.14. Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Molecule Type
5.14.3. By Production
5.14.4. By Application
5.14.5. By Therapeutic Area
5.15. Key Representative Market Participants
5.16. Market Presence (Intensity Map)
6. Western Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
6.3.1. Germany
6.3.2. Italy
6.3.3. France
6.3.4. Spain
6.3.5. U.K.
6.3.6. BENELUX
6.3.7. Nordic
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
6.4.1. Germany
6.4.2. Italy
6.4.3. France
6.4.4. Spain
6.4.5. U.K.
6.4.6. BENELUX
6.4.7. Nordic
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
6.5.1. Standard API
6.5.2. High Potency API
6.6. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
6.6.1. Standard API
6.6.2. High Potency API
6.7. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
6.7.1. In-House
6.7.2. Outsourced
6.8. Market Size (US$ Mn) Forecast By Production, 2017–2027
6.8.1. In-House
6.8.2. Outsourced
6.9. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
6.9.1. Clinical
6.9.2. Commercial
6.10. Market Size (US$ Mn) Analysis By Application, 2017–2027
6.10.1. Clinical
6.10.2. Commercial
6.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
6.11.1. Cardiovascular
6.11.2. Respiratory
6.11.3. Infectious
6.11.4. Metabolic
6.11.5. Oncology
6.11.6. Immunology
6.11.7. Neurology
6.11.8. Urology
6.11.9. Dermatology
6.11.10. Ophthalmology
6.11.11. General Health
6.11.12. Others
6.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
6.12.1. Cardiovascular
6.12.2. Respiratory
6.12.3. Infectious
6.12.4. Metabolic
6.12.5. Oncology
6.12.6. Immunology
6.12.7. Neurology
6.12.8. Urology
6.12.9. Dermatology
6.12.10. Ophthalmology
6.12.11. General Health
6.12.12. Others
6.13. Drivers and Restraints: Impact Analysis
6.14. Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Molecule Type
6.14.3. By Production
6.14.4. By Application
6.14.5. By Therapeutic Area
6.15. Key Representative Market Participants
6.16. Market Presence (Intensity Map)
7. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
7.2.1. Russia
7.2.2. Poland
7.2.3. Rest of Eastern Europe
7.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
7.4.1. Standard API
7.4.2. High Potency API
7.5. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
7.5.1. Standard API
7.5.2. High Potency API
7.6. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
7.6.1. In-House
7.6.2. Outsourced
7.7. Market Size (US$ Mn) Forecast By Production, 2017–2027
7.7.1. In-House
7.7.2. Outsourced
7.8. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
7.8.1. Clinical
7.8.2. Commercial
7.9. Market Size (US$ Mn) Analysis By Application, 2017–2027
7.9.1. Clinical
7.9.2. Commercial
7.10. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
7.10.1. Cardiovascular
7.10.2. Respiratory
7.10.3. Infectious
7.10.4. Metabolic
7.10.5. Oncology
7.10.6. Immunology
7.10.7. Neurology
7.10.8. Urology
7.10.9. Dermatology
7.10.10. Ophthalmology
7.10.11. General Health
7.10.12. Others
7.11. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
7.11.1. Cardiovascular
7.11.2. Respiratory
7.11.3. Infectious
7.11.4. Metabolic
7.11.5. Oncology
7.11.6. Immunology
7.11.7. Neurology
7.11.8. Urology
7.11.9. Dermatology
7.11.10. Ophthalmology
7.11.11. General Health
7.11.12. Others
7.12. Drivers and Restraints: Impact Analysis
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Molecule Type
7.13.3. By Production
7.13.4. By Application
7.13.5. By Therapeutic Area
7.14. Key Representative Market Participants
7.15. Market Presence (Intensity Map)
8. Asia Pacific excluding Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
8.3.1. China
8.3.2. India
8.3.3. ASEAN
8.3.4. Australia and New Zealand
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
8.4.1. China
8.4.2. India
8.4.3. ASEAN
8.4.4. Australia and New Zealand
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
8.5.1. Standard API
8.5.2. High Potency API
8.6. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
8.6.1. Standard API
8.6.2. High Potency API
8.7. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
8.7.1. In-House
8.7.2. Outsourced
8.8. Market Size (US$ Mn) Forecast By Production, 2017–2027
8.8.1. In-House
8.8.2. Outsourced
8.9. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
8.9.1. Clinical
8.9.2. Commercial
8.10. Market Size (US$ Mn) Analysis By Application, 2017–2027
8.10.1. Clinical
8.10.2. Commercial
8.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
8.11.1. Cardiovascular
8.11.2. Respiratory
8.11.3. Infectious
8.11.4. Metabolic
8.11.5. Oncology
8.11.6. Immunology
8.11.7. Neurology
8.11.8. Urology
8.11.9. Dermatology
8.11.10. Ophthalmology
8.11.11. General Health
8.11.12. Others
8.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
8.12.1. Cardiovascular
8.12.2. Respiratory
8.12.3. Infectious
8.12.4. Metabolic
8.12.5. Oncology
8.12.6. Immunology
8.12.7. Neurology
8.12.8. Urology
8.12.9. Dermatology
8.12.10. Ophthalmology
8.12.11. General Health
8.12.12. Others
8.13. Drivers and Restraints: Impact Analysis
8.14. Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Molecule Type
8.14.3. By Production
8.14.4. By Application
8.14.5. By Therapeutic Area
8.15. Key Representative Market Participants
8.16. Market Presence (Intensity Map)
9. Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
9.2.1. Standard API
9.2.2. High Potency API
9.3. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
9.3.1. Standard API
9.3.2. High Potency API
9.4. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
9.4.1. In-House
9.4.2. Outsourced
9.5. Market Size (US$ Mn) Forecast By Production, 2017–2027
9.5.1. In-House
9.5.2. Outsourced
9.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
9.6.1. Clinical
9.6.2. Commercial
9.7. Market Size (US$ Mn) Analysis By Application, 2017–2027
9.7.1. Clinical
9.7.2. Commercial
9.8. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
9.8.1. Cardiovascular
9.8.2. Respiratory
9.8.3. Infectious
9.8.4. Metabolic
9.8.5. Oncology
9.8.6. Immunology
9.8.7. Neurology
9.8.8. Urology
9.8.9. Dermatology
9.8.10. Ophthalmology
9.8.11. General Health
9.8.12. Others
9.9. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
9.9.1. Cardiovascular
9.9.2. Respiratory
9.9.3. Infectious
9.9.4. Metabolic
9.9.5. Oncology
9.9.6. Immunology
9.9.7. Neurology
9.9.8. Urology
9.9.9. Dermatology
9.9.10. Ophthalmology
9.9.11. General Health
9.9.12. Others
9.10. Drivers and Restraints: Impact Analysis
9.11. Market Attractiveness Analysis
9.11.1. By Molecule Type
9.11.2. By Production
9.11.3. By Application
9.11.4. By Therapeutic Area
9.12. Key Representative Market Participants
9.13. Market Presence (Intensity Map)
10. Middle East & Africa Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
10.2.1. GCC Countries
10.2.2. Turkey
10.2.3. Northern Africa
10.2.4. South Africa
10.2.5. Rest of MEA
10.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
10.3.1. GCC Countries
10.3.2. Turkey
10.3.3. Northern Africa
10.3.4. South Africa
10.3.5. Rest of MEA
10.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
10.4.1. Standard API
10.4.2. High Potency API
10.5. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
10.5.1. Standard API
10.5.2. High Potency API
10.6. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
10.6.1. In-House
10.6.2. Outsourced
10.7. Market Size (US$ Mn) Forecast By Production, 2017–2027
10.7.1. In-House
10.7.2. Outsourced
10.8. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
10.8.1. Clinical
10.8.2. Commercial
10.9. Market Size (US$ Mn) Analysis By Application, 2017–2027
10.9.1. Clinical
10.9.2. Commercial
10.10. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
10.10.1. Cardiovascular
10.10.2. Respiratory
10.10.3. Infectious
10.10.4. Metabolic
10.10.5. Oncology
10.10.6. Immunology
10.10.7. Neurology
10.10.8. Urology
10.10.9. Dermatology
10.10.10. Ophthalmology
10.10.11. General Health
10.10.12. Others
10.11. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
10.11.1. Cardiovascular
10.11.2. Respiratory
10.11.3. Infectious
10.11.4. Metabolic
10.11.5. Oncology
10.11.6. Immunology
10.11.7. Neurology
10.11.8. Urology
10.11.9. Dermatology
10.11.10. Ophthalmology
10.11.11. General Health
10.11.12. Others
10.12. Drivers and Restraints: Impact Analysis
10.13. Market Attractiveness Analysis
10.13.1. By Country
10.13.2. By Molecule Type
10.13.3. By Production
10.13.4. By Application
10.13.5. By Therapeutic Area
10.14. Key Representative Market Participants
10.15. Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Market Structure
13.2. Competition Dashboard
13.3. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
13.3.1. Johnson Matthey
13.3.2. Siegfried Holding AG
13.3.3. Pfizer
13.3.4. Sanofi S.A.
13.3.5. Novartis AG,
13.3.6. Bristol-Myers Squibb,
13.3.7. Boehringer Ingelheim GmbH
13.3.8. GlaxoSmithKline PLC, GILEAD Science Inc.,
13.3.9. Albany Molecular Research Inc.
13.3.10. Bachem Holding AG
13.3.11. PCAS
13.3.12. Patheon N.V.
13.3.13. AstraZeneca
13.3.14. Johnson & Johnson
13.3.15. Merck & Co, Inc.
13.3.16. BASF SE
13.3.17. Catalent Inc.
13.3.18. Teva Pharmaceuticals
13.3.19. F. Hoffmann-La Roche Ltd
13.3.20. Cambrex Corporation
13.3.21. GILEAD Science Inc.
14. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2012–2016
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific excluding Japan
14.2.6. Japan
14.2.7. Middle East & Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2017–2027
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific excluding Japan
14.3.6. Japan
14.3.7. Middle East & Africa
14.4. Market Attractiveness Analysis By Region
15. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016
15.2.1. Standard API
15.2.2. High Potency API
15.3. Market Size (US$ Mn) Forecast By Molecule Type, 2017–2027
15.3.1. Standard API
15.3.2. High Potency API
15.4. Market Attractiveness Analysis By Molecule Type
16. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Production
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis By Production, 2012–2016
16.2.1. In-House
16.2.2. Outsourced
16.3. Market Size (US$ Mn) Forecast By Production, 2017–2027
16.3.1. In-House
16.3.2. Outsourced
16.4. Market Attractiveness Analysis By Application
17. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Application
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2012–2016
17.2.1. Clinical
17.2.2. Commercial
17.3. Market Size (US$ Mn) Analysis By Application, 2017–2027
17.3.1. Clinical
17.3.2. Commercial
17.4. Market Attractiveness Analysis By Application
18. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Therapeutic Area
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
18.2.1. Cardiovascular
18.2.2. Respiratory
18.2.3. Infectious
18.2.4. Metabolic
18.2.5. Oncology
18.2.6. Immunology
18.2.7. Neurology
18.2.8. Urology
18.2.9. Dermatology
18.2.10. Ophthalmology
18.2.11. General Health
18.2.12. Others
18.3. Market Size (US$ Mn) Analysis By Therapeutic Area, 2017–2027
18.3.1. Cardiovascular
18.3.2. Respiratory
18.3.3. Infectious
18.3.4. Metabolic
18.3.5. Oncology
18.3.6. Immunology
18.3.7. Neurology
18.3.8. Urology
18.3.9. Dermatology
18.3.10. Ophthalmology
18.3.11. General Health
18.3.12. Others
18.4. Market Attractiveness Analysis By Therapeutic Area
19. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
Small Molecule Api Market Reports - List of Tables
Table 01: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 02: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 03: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 04: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 05: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 06: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 07: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 08: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 09: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 10: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 11: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 12: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 13: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 14: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 15: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 16: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 17: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 18: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 19: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 20: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 21: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 22: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 23: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 24: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 25: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 26: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 27: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 28: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 29: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 30: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 31: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 32: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 33: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 34: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 35: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type
Table 36: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production
Table 37: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 38: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Small Molecule Api Market Reports - List of Figures
Figure 01: North America Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 02: North America Small Molecule API Market Forecast, 2017–2017
Figure 03: North America Standard API Historical Market Size Analysis, 2012–2016
Figure 04: North America Standard API Market Forecast, 2017–2017
Figure 05: North America High Potency API Historical Market Size Analysis, 2012–2016
Figure 06: North America High Potency API Market Forecast, 2017–2017
Figure 07: North America Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 08: North America Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 09: North America Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 10: North America Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 11: North America Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 12: North America Small Molecule API Market Forecast by Clinical, 2017–2017
Figure 13: North America Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 14: North America Small Molecule API Market Forecast by Commercial, 2017–2017
Figure 15: North America Small Molecule API Market Attractiveness Analysis, By Country
Figure 16: North America Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 17: North America Small Molecule API Market Attractiveness Analysis, By Production
Figure 18: North America Small Molecule API Market Attractiveness Analysis, Application
Figure 19: North America Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 20: Western Europe Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 21: Western Europe Small Molecule API Market Forecast, 2017–2017
Figure 22: Western Europe Standard API Historical Market Size Analysis, 2012–2016
Figure 23: Western Europe Standard API Market Forecast, 2017–2017
Figure 24: Western Europe High Potency API Historical Market Size Analysis, 2012–2016
Figure 25: Western Europe High Potency API Market Forecast, 2017–2017
Figure 26: Western Europe Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 27: Western Europe Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 28: Western Europe Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 29: Western Europe Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 30: Western Europe Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 31: Western Europe Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 32: Western Europe Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 33: Western Europe Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 34: Western Europe Small Molecule API Market Attractiveness Analysis, By Country
Figure 35: Western Europe Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 36: Western Europe Small Molecule API Market Attractiveness Analysis, By Production
Figure 37: Western Europe Small Molecule API Market Attractiveness Analysis, Application
Figure 38: Western Europe Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 39: Eastern Europe Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 40: Eastern Europe Small Molecule API Market Forecast, 2017–2017
Figure 41: Eastern Europe Standard API Historical Market Size Analysis, 2012–2016
Figure 42: Eastern Europe Standard API Market Forecast, 2017–2017
Figure 43: Eastern Europe High Potency API Historical Market Size Analysis, 2012–2016
Figure 44: Eastern Europe High Potency API Market Forecast, 2017–2017
Figure 45: Eastern Europe Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 46: Eastern Europe Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 47: Eastern Europe Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 48: Eastern Europe Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 49: Eastern Europe Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 50: Eastern Europe Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 51: Eastern Europe Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 52: Eastern Europe Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 53: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Country
Figure 54: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 55: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Production
Figure 56: Eastern Europe Small Molecule API Market Attractiveness Analysis, Application
Figure 57: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 58: Latin America Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 59: Latin America Small Molecule API Market Forecast, 2017–2017
Figure 60: Latin America Standard API Historical Market Size Analysis, 2012–2016
Figure 61: Latin America Standard API Market Forecast, 2017–2017
Figure 62: Latin America High Potency API Historical Market Size Analysis, 2012–2016
Figure 63: Latin America High Potency API Market Forecast, 2017–2017
Figure 64: Latin America Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 65: Latin America Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 66: Latin America Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 67: Latin America Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 68: Latin America Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 69: Latin America Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 70: Latin America Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 71: Latin America Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 72: Latin America Small Molecule API Market Attractiveness Analysis, By Country
Figure 73: Latin America Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 74: Latin America Small Molecule API Market Attractiveness Analysis, By Production
Figure 75: Latin America Small Molecule API Market Attractiveness Analysis, Application
Figure 76: Latin America Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 77: APEJ Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 78: APEJ Small Molecule API Market Forecast, 2017–2017
Figure 79: APEJ Standard API Historical Market Size Analysis, 2012–2016
Figure 80: APEJ Standard API Market Forecast, 2017–2017
Figure 81: APEJ High Potency API Historical Market Size Analysis, 2012–2016
Figure 82: APEJ High Potency API Market Forecast, 2017–2017
Figure 83: APEJ Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 84: APEJ Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 85: APEJ Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 86: APEJ Small Molecule API Market Forecast By Outsourced, 2017–2017
Figure 87: APEJ Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 88: APEJ Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 89: APEJ Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 90: APEJ Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 91: APEJ Small Molecule API Market Attractiveness Analysis, By Country
Figure 92: APEJ Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 93: APEJ Small Molecule API Market Attractiveness Analysis, By Production
Figure 94: APEJ Small Molecule API Market Attractiveness Analysis, Application
Figure 95: APEJ Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 96: MEA Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 97: MEA Small Molecule API Market Forecast, 2017–2017
Figure 98: MEA Standard API Historical Market Size Analysis, 2012–2016
Figure 99: MEA Standard API Market Forecast, 2017–2017
Figure 100: MEA High Potency API Historical Market Size Analysis, 2012–2016
Figure 101: MEA High Potency API Market Forecast, 2017–2017
Figure 102: MEA Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 103: MEA Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 104: MEA Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 105: MEA Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 106: MEA Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 107: MEA Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 108: MEA Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 109: MEA Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 110: MEA Small Molecule API Market Attractiveness Analysis, By Country
Figure 111: MEA Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 112: MEA Small Molecule API Market Attractiveness Analysis, By Production
Figure 113: MEA Small Molecule API Market Attractiveness Analysis, Application
Figure 114: MEA Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 115: Japan Small Molecule API Historical Market Size Analysis, 2012–2016
Figure 116: Japan Small Molecule API Market Forecast, 2017–2017
Figure 117: Japan Standard API Historical Market Size Analysis, 2012–2016
Figure 118: Japan Standard API Market Forecast, 2017–2017
Figure 119: Japan High Potency API Historical Market Size Analysis, 2012–2016
Figure 120: Japan High Potency API Market Forecast, 2017–2017
Figure 121: Japan Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 122: Japan Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 123: Japan Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
Figure 124: Japan Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 125: Japan Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 126: Japan Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 127: Japan Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 128: Japan Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 129: Japan Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 130: Japan Small Molecule API Market Attractiveness Analysis, By Production
Figure 131: Japan Small Molecule API Market Attractiveness Analysis, Application
Figure 132: Japan Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
Figure 133: Global Small Molecule API Market Size Analysis, 2012–2016
Figure 134: Global Small Molecule API Market Forecast, 2017–2017
Figure 135: Global Standard API Historical Market Size Analysis, 2012–2016
Figure 136: Global Standard API Market Forecast, 2017–2017
Figure 137: Global High Potency API Historical Market Size Analysis, 2012–2016
Figure 138: Global High Potency API Market Forecast, 2017–2017
Figure 139: Global Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
Figure 140: Global Small Molecule API Market Forecast, By In-House, 2017–2017
Figure 141: Global Small Molecule API Historical Market Size Analysis By, Outsourced, 2012–2016
Figure 142: Global Small Molecule API Market Forecast, By Outsourced, 2017–2017
Figure 143: Global Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
Figure 144: Global Small Molecule API Market Forecast, By Clinical, 2017–2017
Figure 145: Global Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
Figure 146: Global Small Molecule API Market Forecast, By Commercial, 2017–2017
Figure 147: Global Small Molecule API Market Attractiveness Analysis, By Country
Figure 148: Global Small Molecule API Market Attractiveness Analysis, By Molecule Type
Figure 149: Global Small Molecule API Market Attractiveness Analysis, By Production
Figure 150: Global Small Molecule API Market Attractiveness Analysis, Application
Figure 151: Global Small Molecule API Market Attractiveness Analysis, By Therapeutic Area